Hostname: page-component-77c89778f8-m8s7h Total loading time: 0 Render date: 2024-07-22T06:07:40.491Z Has data issue: false hasContentIssue false
  • English
  • Français

Sodium Valproate in the Treatment of the Intractable Childhood Epileptic

Published online by Cambridge University Press:  18 September 2015

D.L. Keene ,
K. Metrakos ,
G.V. Watters  and
A. Sherwin
D.L. Keene*
Affiliation:
Neurology Department, Montreal Children’s Hospital and the Montreal Neurological Institute, Montreal, Quebec
K. Metrakos
Affiliation:
Neurology Department, Montreal Children’s Hospital and the Montreal Neurological Institute, Montreal, Quebec
G.V. Watters
Affiliation:
Neurology Department, Montreal Children’s Hospital and the Montreal Neurological Institute, Montreal, Quebec
A. Sherwin
Affiliation:
Neurology Department, Montreal Children’s Hospital and the Montreal Neurological Institute, Montreal, Quebec
*
Children’s Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario K1H 8L1
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Sixty-five children with seizure disorders, who had been treated with multiple anticonvulsants but were poorly controlled, were selected from the Montreal Children’s Hospital Convulsive Disorder Clinic and Neurology Service and were treated with sodium valproate (valproate). All types of seizure disorders were included in the group.

Rapid oral absorption of the drug lead to peak plasma levels in one to three hours (later peaks occurring if administered after meals). A mean plasma half-life of 12.8 hours was calculated. Correlation between oral dose and plasma levels was poor. The side effects which occurred in this study were trivial. Drug interactions occurred with phenobarbital, diphenylhydantoin and clonazepam.

Sixty percent of patients had a greater than 50% reduction in seizure frequency with sodium valproate, but the best response was in generalized absence seizures. Since all types of seizures responded to some degree, a trial of sodium valproate is warranted in intractable seizure disorders of childhood regardless of classification.

Type
Hypothesis
Information
Canadian Journal of Neurological Sciences , Volume 9 , Issue 3 , August 1982 , pp. 307 - 311
Copyright
Copyright © Canadian Neurological Sciences Federation 1982

References

Barnes, S.E. and Bower, S.E. – “Sodium Valproate in the Treatment of Intractable Childhood Epilepsy” – Develop Med. Child. Neurol. 17:175 (1975).CrossRefGoogle ScholarPubMed
Bruni, J., Wilder, B.J., Perchalski, R.J., Hammond, E.J., and Villareal, H.J. – “Valproic Acid and Plasma Levels of Phenobarbital” – Neurol. (Minneal) 1:94 (1980).CrossRefGoogle Scholar
Bruni, J., Wilder, B.J., Willmore, L.J., and Barbour, B. – “Valproic Acid Plasma Levels of Phenytoin” -Neurol(Minneap) 29:904 (1979).Google ScholarPubMed
Carraz, G., Fau, R., Chateau, R. and Bonnin, J. – “Communications à propos des premiers essais cliniques sur L’activité anti-épileptique de L’acid n-dipropylacétique (sel de Na)” Ann Med. Psychol 122:577 (1964).Google Scholar
Covanis, A. and Jeavons, P.M. – “Once Daily Sodium Valproate in the Treatment of Epilepsy” – Devel. Med. Child. Neurol. 22:204 (1980).CrossRefGoogle ScholarPubMed
Gerber, N., Dickinson, R.G., Harland, R.C., Lynn, R.K., Houghton, D., Antonia, J.I. and Schmishock, J.C. – “Reye-like Syndrome Associated with Valproic Acid Therapy” J. Ped. 95:142 (1979).CrossRefGoogle ScholarPubMed
Haigh, D. and Forsythe, W.I. – “The Treatment of Childhood Epilepsy with Sodium Valproate” – Develop. Med. Child. Neurol. 17:743 (1975).CrossRefGoogle ScholarPubMed
Hassan, M.N., Laljee, H.C.K., and Parsonage, M.J. – “Sodium Valproate in the Treatment of Resistant Epilepsy” – Acta Neurol Scand. 54:209 (1976).CrossRefGoogle ScholarPubMed
Jeavons, P. and Clark, J.E. – “Sodium Valproate in Treatment of Epilepsy” – Brit. Med. J. 2:584 (1974).CrossRefGoogle ScholarPubMed
Jeavons, P.M., Clark, J.E. and Maheshwasi, M.C. – “The Treatment of Generalized Epilepsies on Valproate (Epilim) – Devel. Med. Child. Neurol. 19:9 (1977).CrossRefGoogle ScholarPubMed
Meunier, H., Carraz, G., Neunier, Y., Eymard, P. and Aimard, M. “Proprites” pharmacodynamiques de l’acid n-dipropylacetique-Therapie 18:435 (1964).Google Scholar
Odusote, K. and Sherwin, A. – “A Simple Direct Extraction Method for gas-liquid chromatographic Determination of Valproic Acid in Plasma” – Therapeutic Drug Monitoring 3:103 (1981).CrossRefGoogle ScholarPubMed
Pinder, R.M., Brodgen, R.N., Speight, T.M. and Avery, G.S. “Sodium Valproate: A Review of its Pharmacological Properties and Therapeutic Efficacy in Epilepsy” – Drugs 13:81 (1977).CrossRefGoogle ScholarPubMed
Richens, A. and Ahmad, S. – “Controlled Trial of Sodium Valproate in Severe Epilepsy” – Brit Med. J. 1:255 (1975).Google Scholar
Ruuskanen, I., Kilpelainen, J.O. and Rickkinen, P.J. – “Side Effects of Sodium Valproate during long-term Treatment in Epilepsy” – Acta. Neurol. Scand. 60:125 (1979).Google ScholarPubMed
Sherard, E.S., Steinman, G. and Couri, D. – “Treatment of Childhood Epilepsy with Valproic Acid: Results of the First 100 Patients in a 6 month Trial” – Neurol (Minneap) 30:31 (1980).CrossRefGoogle Scholar
Sillanpaa, M. and Donner, M. – “Experiences on the use of Dipropylacetate in the Treatment of Childhood Epilepsy” – Acta Paediatr. Scand. 65:209 (1976).CrossRefGoogle ScholarPubMed
Simon, D. and Penvy, J.K. – “Sodium di-N-propylacetate (DPA) in the treatment of Epilepsy, a Review” – Epilepsia 16:549 (1975).CrossRefGoogle ScholarPubMed
Vining, E.P.G.I., Botsford, E. and Freeman, J.M. – “Valproate Sodium in Refractory Seizures” – Am. J. Dis. Child 133:274 (1979).CrossRefGoogle ScholarPubMed
Volzke, E. and Doose, H. – “Dipropylacetate (Depakine Ergenyl) in the Treatment of Epilepsy” – Epilepsia (Amst) 14:185 (1973).CrossRefGoogle ScholarPubMed
Wilder, B.J., Willmore, L.J., Bruni, J. and Villareal, H.J. “Valproic Acid interaction with other Anticonvulsant Drugs” -Neurol. Minneap 28:892 (1978).CrossRefGoogle ScholarPubMed